Walleye Trading’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,800
Closed -$222K 4742
2025
Q4
$222K Buy
5,800
+1,900
+49% +$61.8K ﹤0.01% 3334
2025
Q3
$93.2K Buy
+3,900
New +$73.3K ﹤0.01% 3736
2022
Q1
Sell
-7,900
Closed -$245K 5932
2021
Q4
$245K Sell
7,900
-10,500
-57% -$296K ﹤0.01% 3686
2021
Q3
$446K Buy
+18,400
New +$338K ﹤0.01% 3031
2021
Q1
Sell
-12,700
Closed -$346K 5316
2020
Q4
$346K Buy
+12,700
New +$297K ﹤0.01% 3003
2020
Q3
Sell
-600
Closed -$12K 4636
2020
Q2
$12K Buy
+600
New +$9.55K ﹤0.01% 4051
2020
Q1
Sell
-200
Closed -$3K 4584
2019
Q4
$3K Hold
200
﹤0.01% 4140
2019
Q3
$2K Buy
+200
New +$3.31K ﹤0.01% 3930
2019
Q2
Sell
-15,000
Closed -$339K 4503
2019
Q1
$339K Buy
15,000
+14,100
+1,567% +$312K ﹤0.01% 2601
2018
Q4
$20K Sell
900
-36,400
-98% -$905K ﹤0.01% 4344
2018
Q3
$1.07M Buy
+37,300
New +$1.07M 0.01% 1997
2018
Q1
Sell
-24,300
Closed -$513 4815
2017
Q4
$513 Buy
+24,300
New +$555K ﹤0.01% 2571

Other funds holding TVTX

Walleye Trading's TVTX Position: Q1 2026 in Review

Walleye Trading sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 374 shares — an estimated $14.3K sold.

Walleye Trading first reported a position in TVTX in Q2 2015 and held it in 17 quarters. The position peaked at $785K in Q3 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Walleye Trading reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 374 Travere Therapeutics shares in Q1 2026, an estimated $14.3K.
  • Walleye Trading first reported a position in Travere Therapeutics in Q2 2015 and held it in 17 quarters.
  • Walleye Trading's Travere Therapeutics position peaked at $785K in Q3 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.